QR Code

Exposure to alendronate is associated with a lower risk of bone metastases in osteoporotic women with early breast cancer

Background: Bisphosphonate (BP) treatment to prevent bone loss in breast cancer patients is already well established. However, data on the association between oral BP exposure before cancer diagnosis and disease outcomes in patients with early breast cancer are still scarce. Limited information is a...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Vanessa Rouach, Inbal Goldshtein, Ido Wolf, Raphael Catane, Gabriel Chodick, Amit Iton, Naftali Stern, Daniel Cohen
Format: Artigo
Langue:Inglês
Publié: Elsevier 2018-09-01
Collection:Journal of Bone Oncology
Accès en ligne:http://www.sciencedirect.com/science/article/pii/S2212137418300496
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!